FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	burden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* THOMAS TOM C					2. Issuer Name and Ticker or Trading Symbol Vincerx Pharma, Inc. [VINC]								(Che	ck all app Direc	,		10%	Issuer Dwner (specify	
(Last) 260 SHE	•	rst) (M /ENUE, SUITE	Middle)	3. Date of Earliest Tran 12/14/2022					saction (Month/Day/Year)					X		below) See Rei		below	
(Street) PALO A	LTO CA	A 9	4306		4. If <i>i</i>	Amend	ment,	Date o	of Origir	nal File	ed (Month/Da	y/Year)		6. Ind Line)	Form	filed by O	ne Rep	oorting Pe	
(City)	(St	ate) (Z	Zip)													Person			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				Execution Date,						Acquired (A) or (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	,	Transact (Instr. 3	tion(s)			(Instr. 4)
Common Stock 12/14/20				022	22		P		7,000	A	\$0.8	33(1)	10,000		I		The Thomas Family Revocable Trust, dated 9/11/2012		
Common Stock															209,935(2)		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)				4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expira (Monti	ation D		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		r.	Price of erivative ecurity istr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Owners Form: Direct (I or Indire (I) (Instr		Beneficial Ownership t (Instr. 4)	
				Code		v	/ (A) (D)		Date Exerc	isable	Expiration Date	Title	of Shares						

Explanation of Responses:

- Represents actual price.
- 2. Includes 2,996 shares of common stock acquired under the Vincerx Pharma, Inc. 2021 Employee Stock Purchase Plan on May 13, 2022.

Remarks:

General Counsel and Chief Legal Officer

/s/ Tom C. Thomas 12/14/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.